drugset / Trial / NCT02382640

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

NCT02382640

Phase 1 Completed 36 enrolled Takeda
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the effect of antacid administration, and its timing, on the bioavailability of a single dose of febuxostat extended-release (XR) 80 mg.

Timeline

Start
2015-03
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aluminum hydroxide Unknown 200 mg Oral
Subject Febuxostat Small molecule 80 mg Oral
Subject Simethicone Other / unclassified 20 mg Oral
Subject magnesium hydroxide Unknown 200 mg Oral

Indications

No indication recorded.